What’s Happening in the RRP Community
What’s Happening in the RRP Community
Stay informed on the latest developments in RRP research, treatment advances, clinical trial opportunities, and advocacy efforts. This is your source for news that matters to patients, caregivers, and clinicians navigating the evolving landscape of recurrent respiratory papillomatosis care.
BackTable ENT Podcast Discusses Immunotherapy for Adults with RRP
Dr. Aaron Friedman joins the BackTable ENT podcast to discuss immune-directed therapy for RRP, including the FDA-approved PAPZIMEOS vaccine and what clinical trial data reveal about durable treatment responses in adults.
First Patients Dosed With Papzimeos: A Historic Milestone for the RRP Community
After years of advocacy and research, the first patients have now received doses of Papzimeos. RRPF President Kim McClellan reflects on what this historic moment means for our community.
RRPF Hosts Webinar Following the FDA Approval of Papzimeos
The RRPF invited Dr. Clint Allen, Dr. Simon Best, Dr. Geoffrey Young, and Precigen to our webinar series to chat about Papzimeos and answer a few of the questions from our RRP community.
Hope Realized: FDA Approves Papzimeos for Adults with Recurrent Respiratory Papillomatosis
The FDA has approved Papzimeos, the first and only treatment for adults with RRP. RRPF celebrates this historic milestone and reflects on what it means for our community.